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Abstract
Background: Asylum seekers and refugees (AS&Rs) experience impaired mental health and wellbeing, related to
stresses in their country of origin, experiences in transit and reception on arrival, including significant barriers to
accessing mainstream services. Their contact with health care is often crisis-driven and mediated through non-
governmental organisations (NGOs).
Problem Management Plus (PM+) is a psychosocial intervention recommended by the World Health Organisation
to address distress experienced by adults affected by humanitarian crises. We are investigating its application for
the first time in a high-income country.
Methods: In a pilot randomised controlled trial (RCT), PM+ will be delivered to AS&Rs in contact with NGOs in
Liverpool City Region, UK by lay therapists who have lived experience of forced migration. Following systematic
review and stakeholder engagement, PM+ has been adapted to the local context, and lay therapists have been
trained in its delivery.
We will assess the feasibility of conducting a three-arm RCT of five 90-min sessions of PM+, delivered individually or
in groups by lay therapists to AS&Rs experiencing emotional distress and functional impairment, compared with
each other and with usual support offered by local NGOs. Distress and impairment at baseline will be measured by
the Hospital Anxiety and Depression Scale (HADS) and the WHO Disability Assessment Schedule (WHO-DAS). We
aim to recruit 105 participants, 35 per arm.
Primary health outcomes are anxiety and depressive symptoms at 3 months, measured by HADS. Secondary
outcomes include subjective wellbeing, functional status, progress on identified problems, presence of post-
traumatic stress disorder and depressive disorder and service usage. Longer-term impact will be assessed at 6
months post baseline, on the same parameters.
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We will assess the feasibility of conducting a full RCT in relation to the following elements: recruitment and
retention of lay therapists and study participants; fidelity of delivery of PM+; and suitability of the study measures,
including any linguistic or cultural barriers.
Discussion: We will use these findings to specify the parameters for a full RCT to test the effectiveness and cost-
effectiveness of PM+ in reducing emotional distress and health inequalities, and improving functional ability and
wellbeing, amongst asylum seekers and refugees.
Trial registration: ISRCTN, ID: ISRCTN15214107. Registered on 10 September 2019.
Keywords: Asylum seekers, Refugees, Mental health, Psychosocial intervention, Problem management, Lay
therapists, High-income country, Pilot randomised controlled trial
Background
Introduction
The United Nations Refugee Agency estimates that 71
million people throughout the world have been forced to
flee their homes as the number of protracted conflicts
has increased. This has created more than 26 million ref-
ugees worldwide, of whom an estimated 126,720 live in
the UK [1]. UK Home Office figures indicate there were
34,354 asylum applications in the UK (main applicants
only) in the year ending September 2019. During that
year the UK offered asylum, humanitarian protection, al-
ternative forms of leave and resettlement to 19,480
people; there were 35,043 cases pending initial decision,
of which 57% were more than 6months old [2]. Many
applications are initially refused as a result of a complex
system that makes it difficult for asylum seekers and ref-
ugees (AS&Rs) to provide the evidence needed to meet
the criteria for gaining asylum.
AS&Rs have a higher prevalence of psychological
morbidity, including depression, anxiety and post-
traumatic stress disorder (PTSD), and functional im-
pairment than other migrant groups and local major-
ity populations [3–5]. Mental health problems are
particularly prevalent amongst war refugees [6], with
rates of PTSD up to 10 times higher than in the gen-
eral population [7, 8]. Persistence of mental health
problems after arrival in a host country is related to
poor socio-economic conditions, acculturation-related
stressors, economic uncertainty and ethno-racial dis-
crimination [5, 9]. As a result, AS&Rs encounter ex-
tensive barriers to accessing health care [5, 10] and
have substantial unmet mental health needs [11]. In
the UK, the situation is especially problematic for asy-
lum seekers without leave to remain who are at risk
of destitution yet are required to pay for specialist
health care [12, 13].
Psychosocial interventions for AS&Rs resettled in
high-income countries (HICs) may provide significant
benefits; however, there are few studies of good quality
[14, 15]. Evidence for the applicability of psychological
interventions by non-specialists in low and middle-
income countries (LMICs) has increased significantly
[16–19]. Many countries, including the UK, are seeking
to improve health care delivery by extending the roles of
health professionals [20], increasing workforce capacity
and enhancing quality of care [21]. Innovations devel-
oped in LMICs, including task-sharing [22] and the
Common Elements Treatment Approach [23], have the
potential to address current challenges for mental health
care in HICs [24], notably the lack of human resources
to deliver mental health services to those in need.
Problem Management Plus (PM+), is a manua-
lised, brief, multi-component intervention [25], rec-
ommended by the World Health Organisation
(WHO) as part of its mhGAP guidelines (http://
www.who.int/mental_health/mhgap/en/). It is specif-
ically developed to be amenable to cultural and lin-
guistic adaptation for the local context. Based on
evidence-based problem-solving and behavioural
techniques, the intervention is trans-diagnostic by
which we mean that it applies the same intervention
strategies across various common mental health
problems that clients may be experiencing. Address-
ing multiple problems at one time through shared
emotional mechanisms is efficient, reducing the
practical challenge of making differential diagnoses
and learning multiple treatment manuals for differ-
ent mental health diagnoses [26, 27].
Rationale
PM+ has shown significant benefit in trials in LMICs
[25, 28, 29]. However, to date, there is no evidence of
feasibility, effectiveness or cost-effectiveness of interven-
tions such as PM+ offered by lay therapists to AS&Rs in
HICs.
The rationale for undertaking a pilot trial of PM+ for
AS&Rs, rather than proceeding to a full multi-centre
trial, is that there are several areas of uncertainty regard-
ing trial viability. These include the feasibility of recruit-
ing and retaining AS&Rs as study participants, the
fidelity of intervention delivery, and the acceptability and
utility of the proposed study measures [30]. There may
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also be inequalities in mental health and wellbeing be-
tween AS&R groups, depending on their age, gender, na-
tionality, education, occupational status, length of stay,
access to resources and their current legal status in the
UK which could inform the design of a full trial. As
Northwest England has the largest number of asylum
seekers in dispersal accommodation in England (9521 in
September 2019) it is a suitable setting for the pilot trial.
Preparatory work
The PROSPER Pilot trial (hereafter referred to as the
PROSPER Pilot) builds on a preparatory phase aimed at
developing the research team’s understanding of relevant
issues, engaging with stakeholders, adapting the inter-
vention and training the facilitators.
We conducted a systematic review (PROSPERO 2018
CRD42018104453) of barriers and facilitators to the up-
take of psychosocial interventions delivered by lay thera-
pists to improve mental health and wellbeing of asylum
seekers and migrants. We also undertook six focus
groups with local service providers and potential service
users, and held two open meetings for stakeholders, to
gather views about the mental health needs of AS&Rs
and the potential utility of PM+.
As a result, we made the following contextual modifi-
cations to promote uptake and relevance of the PROS-
PER Pilot:
 Focus on English, Arabic, Farsi and Urdu, identified
as four most common languages currently spoken
by AS&Rs in Liverpool City Region
 Decision to exclude new arrivals and those in
temporary accommodation: on grounds of (a) high
probability of dispersal and hence unavailability for
intervention and/or follow-up; and (b) low probabil-
ity of being registered with a general practitioner
(GP) and hence being unable to access trial safe-
guarding procedures
 Alteration to text of PM+ manuals to reflect life in
western urban settings, rather than South Asian
rural settings: e.g. ‘home’ not ‘hut’, ‘reading’ not
‘rearing poultry’, ‘visit job centre’ not ‘speak with
village elder’
 Adapting the group PM+ case studies to include
men
 Matching therapists and participants on basis of
gender and language, but not on basis of religion,
politics or culture
 Identification of accessible ‘safe spaces’ for research
interviews and delivery of PM+ sessions, including
availability of child care
 Reimbursement of travel expenses for lay therapists
and participants
 Supervision and support of lay therapists to include
boundary issues between therapy and involvement
in participants’ lives, since the shared lived-
experience of the asylum process takes this study be-
yond the boundaries that have been apparent in
other contexts
Training
Person Shaped Support (PSS) is a health and social care
charity, responsible for training in and delivery of the
PROSPER intervention. PSS provides a wide array of ser-
vices, including Spinning World, a specialist psycho-
logical therapy service for AS&Rs and others who have
experienced human-right abuses and traumatic events.
Two Wellbeing Mentors were appointed by PSS in
September 2018. The following month they and their
supervisor received 5 days of intensive training from two
PM+ Master Trainers (from Liverpool and Amsterdam).
This focussed on the delivery of the PM+ intervention
strategies in both individual and group modalities, and
on skills in training and supervising lay therapists. Sub-
sequently the Wellbeing Mentors completed practice
cases to embed their skills, and receive regular monthly
supervision from one of the PM+ Master Trainers which
will continue throughout the study.
Fifteen people with lived experience of the asylum
process were offered training lay therapists, after a re-
cruitment procedure organised through PSS. Training
began in March 2019 and included education in mental
disorders, basic helping skills, delivery of intervention
strategies and self-care. Lay therapists received a total of
8 days of training, and were trained to deliver either in-
dividual or group PM+. This was followed by training
cases and a competency assessment. Ten lay therapists
successfully completed training and were assessed as
competent: six in individual PM+ (two Farsi-speaking
men, one Arabic-speaking man, and three women,
whose languages are Urdu, Farsi and English) and four
in group PM+ (one Urdu-speaking man and three
women, whose languages are Arabic, Turkish and Thai).
Methods
Aim and objectives
This pilot trial is part of the PROSPER feasibility study,
the overall aim of which is to determine whether it is
possible to conduct a randomised controlled trial (RCT)
in the UK of the evidence-based PM+ psychosocial
intervention, delivered by lay therapists for distressed
and functionally impaired asylum seekers and refugees.
The primary objective of the PROSPER Pilot is to pro-
vide preliminary information on the potential effective-
ness of group or individual PM+ versus standard care
for AS&Rs, assessed using severity of combined anxiety
and depressive symptoms at 13 weeks post baseline,
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measured using the Hospital Anxiety and Depression
Scale (HADS).
The secondary objectives are to provide preliminary
information on the potential effectiveness and cost-
effectiveness of group or individual PM+ versus standard
care for AS&Rs with regards to:
Severity of combined anxiety and depressive
symptoms at 26 weeks
Subjective wellbeing
Functional impairment
Progress on problems for which an individual has
sought help
Presence of post-traumatic stress disorder
Presence of depressive disorder
Use of services and supports from National Health
Service (NHS), social care and voluntary organisations
Design and setting
PROSPER Pilot is designed as a three-arm pilot study,
with the features of a proposed future definitive RCT.
Participants will be randomised to receive individual
PM+, group PM+ or the control (no PM+), in a ratio of
1:1:1.
The pilot trial is being conducted in Liverpool City Re-
gion. It utilises collaborative working between three uni-
versities (University of Liverpool, Liverpool John Moores
University and Bangor University) and three non-
governmental organisations (NGOs) offering advice and
support to AS&Rs: PSS, Asylum Link, and British Red
Cross, local NGOs whose primary function is to provide
advice and support for AS&Rs.
Participants
Trial participants will be asylum seekers and refugees.
This includes those with pre-asylum status; those who
have been offered either discretionary or indefinite leave
to remain in the UK; those whose applications for leave
to remain are pending or have been refused; those with
humanitarian protection; those with refugee status;
stateless people; and people on the vulnerable person re-
settlement programme.
The other inclusion criteria are:
 Aged ≥ 18 years (self-reported)
 A score of ≥ 8 on either the depression or anxiety
subscale of the HADS [31], and a score of ≥ 17 on
the World Health Organisation Disability
Assessment Schedule 2.0 (WHODAS) [32]
 Have conversational English, as self-assessed by the
potential participant
 Being registered with a GP in Liverpool City Region
 Are willing to provide relevant socio-economic data
 Have provided written informed consent
The exclusion criteria are:
 New arrivals to the UK (less than 28 days), due to
high likelihood of dispersal outside the region
 In reception centres, usually known as Initial
Accommodation, and receiving temporary financial
support under Section 98 of the Immigration and
Asylum Act 1999 for less than 28 days, also due to
high likelihood of dispersal outside the region
 Imminent risk of suicide: assessed by researchers
using formal protocols with supervision and
arbitration from qualified health care professionals
 Complex mental disorder (bipolar disorder/manic
depression, or schizophrenia): assessed by a
researcher on the basis of: participant self-reporting
a diagnosis; and/or participant currently in receipt of
antipsychotic medication, defined as medication
listed in British National Formulary Chapter 2, sec-
tion 2.3 (bipolar disorder and mania) and section 2.6
(psychoses and schizophrenia). If required, further
clinical assessment will occur using standard formal
protocols
 Cognitive impairment (moderate/severe intellectual
disability, any dementia). Assessed by a researcher
on the basis of participant or carer self-report
 Substance misuse: assessed by a researcher on the
basis of participant response to the question: ‘are
you currently having problems with alcohol,
cocaine, marijuana or any other drugs?’ If the
response is ‘yes’ or equivocal, then the participant
will be excluded. If required, further clinical
assessment will occur using standard formal
protocols
 Currently receiving a formal psychological therapy,
to avoid potential confounding effects
Outcome measures
Specific outcome measures, which are candidates for in-
clusion in any future definitive trial of PM+ for AS&Rs,
will be tested as part of PROSPER Pilot. These are sum-
marised in Table 1.
 HADS is a well-established, 14-item scale consisting
of 2 subscales: HADS-A (anxiety; 7 items; possible
score range, 0–21) and HADS-D (depression; 7
items; possible score range, 0–21). Higher scores in-
dicate more anxiety and/or depression. HADS has
been widely used across cultures; it is sensitive to
change over time and has good internal consistency,
reliability and validity [38]
 WHO-5 is validated in international studies for both
clinical and psychometric properties and is available
in many languages
Rawlinson et al. Trials          (2020) 21:367 Page 4 of 14
 WHODAS is applicable across all health states
including mental disorders. It has good validity in
terms of internal consistency, test-retest reliability,
and agreement with other measures of disability
across countries
 PSYCHLOPS has internal consistency, convergent
validity with measures of emotional distress, and is
sensitive to change. It covers 3 domains: problems
(2 questions), functioning (1 question) and well-
being (1 question)
 PCL-5 has good psychometric properties for
diagnostic accuracy and internal consistency
 PHQ-9 is based on DSM-IV depression diagnostic cri-
teria. Total severity score ranges from 0 to 27, with 10
as conventional cut-off to diagnose depressive disorder
 The CSRI has been adapted for the PROSPER trial
to include health, social care and voluntary services
with the potential to be used by asylum seekers and
refugees
Other elements of PROSPER Pilot will be assessed and
used to inform the feasibility of conducting a full trial, as
specified in Table 2.
The feasibility of progression to a definitive, multi-
centre RCT will be informed by the extent to which the
criteria below have been met using a go, amend, stop
system, as specified in Table 3.
If the criteria meet ‘amend’ targets, reasons for this will
be investigated with an aim to identify aspects that are
amenable to change. If the criteria meet ‘stop’ targets, rea-
sons will be analysed and discussed within the Project Man-
agement Group (PMG) and with independent oversight
committees. If it is determined that these rates cannot be
improved then a full trial will not be recommended.
Other progression criteria involving data from PROS-
PER Pilot that will be assessed by the research team are:
 Recruitment of supervisors and lay therapists
 Retention of lay therapists
 Acceptability of outcome measures
 Whether clinically important improvement in
outcomes are plausible
Intervention
The PM+ intervention consists of five weekly, face-to-
face sessions, delivered either one-to-one or in groups.
Table 1 PROSPER outcome measures
Objective Outcome measures Time point(s) of evaluation
Efficacy:
Severity of combined anxiety and depressive
symptoms
Hospital Anxiety and Depression Scale
(HADS) [31]
Baseline, 13-week and 26 week follow
up assessments
Functional impairment WHO Disability Assessment Schedule
(WHODAS) [32]
Subjective wellbeing WHO-5 Wellbeing Index [33]
Progress with problems for which participant has
sought help
Psychological Outcomes Profile (PSYCHLOPS)
[34]
Post-traumatic stress disorder (PTSD) Post-traumatic Stress Disorder Checklist for
DSM-5 (PCL-5) [35]
Depressive disorder 9-item Patient Health Questionnaire (PHQ-9)
[36]
Health economics:
Use of services and supports from NHS, social care
and voluntary sectors
Adapted Client Service Receipt Inventory (CSRI)
[37]
Baseline, 13-week and 26-week follow-up
assessments
Table 2 PROSPER feasibility measures
Objective Outcome measure Time point(s) of
evaluation
To assess the feasibility of the proposed procedures for recruiting
distressed AS&Rs as study participants
Number of asylum seekers and refugees (AS&Rs)
recruited
Baseline
To assess feasibility of randomisation Successful randomisation of participants Baseline
(randomisation)
To assess the feasibility of retaining study participants through to trial
completion
Number of study participants in the trial (assessed in
individual arms)
26 weeks
To assess the acceptability and utility of specified primary and secondary
outcome measures
Completion of study measures and estimation of
between group differences
Evaluation of outcome measures
Baseline, 13 weeks,
26 weeks
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The first session opens with psychoeducation, including
information on common reactions to adversity, the ra-
tionale for PM+, goal-setting, and brief motivational
interviewing. Sessions 1 to 4 each introduce an interven-
tion strategy: (1) Managing Stress (slow-breathing exer-
cise); (2) Managing Problems (using problem solving
techniques); (3) Get Going, Keep Doing (applying behav-
ioural activation techniques) and (4) Strengthening So-
cial Support. These strategies are applied by participants
during the intervention session to problems they are fa-
cing. Each strategy is reviewed in subsequent sessions,
with application of strategies between sessions encour-
aged to enhance learning through repetition. The final
session involves a revision of learning, education on pre-
venting relapse, and (for group PM+) ends with a cultur-
ally appropriate closing ceremony.
To enhance accessibility for groups, the group PM+
intervention is structured around locally relevant and
appropriate pictorial materials and adopts a narrative
format to support engagement and individual disclosure
of personal difficulties which can be more difficult in a
group format. Specifically, a case example of a woman
or a man (depending on the gender of group partici-
pants) experiencing common functioning and emotional
problems is shared each week, with participants follow-
ing their progress through the PM+ group.
All PM+ sessions will take place at mutually conveni-
ent and safe locations, where support is available if re-
quired. Sessions will be delivered within organisations
which have on-site staff with experience and training in
managing emotional distress. No face-to-face sessions
will take place in the home of either a participant or a
lay therapist. There will be no special criteria for discon-
tinuing or modifying the allocated interventions.
Protocol adherence
Consistent with an apprenticeship model [39], protocol
adherence is ensured through regular (at least fort-
nightly) supervision of the lay therapists provided by two
Wellbeing Mentors. Involving all individual or group lay
therapists in a group, supervision will last up to 3 h and
will entail reviewing the progress of intervention deliv-
ery, including case management of participants and add-
itional refresher training on intervention components.
The group PM+ lay therapists will receive the same as
individual PM+ lay therapists, in addition to refresher
training on group facilitation skills, through role-play.
The Wellbeing Mentors are in turn provided with
supervision by one of the Master Trainers, conducted at
least monthly during the trial and lasting 2 h. In
addition, Wellbeing Mentors will have the day-to-day
support of their line manager at PSS who also partici-
pated in the 5-day PM+ training with the Master
Trainers, and who participates in the monthly supervi-
sion sessions with the Master Trainer to ensure supervi-
sion consistency.
Intervention fidelity will be monitored through inde-
pendent observations of 15% of randomly selected ses-
sions of each lay therapist against tailored checklists,
conducted by the Wellbeing Mentors. Session logs (per
participant) will be completed by lay therapists after
each PM+ session and will capture information regard-
ing timing, length and content of sessions. The logs will
be passed to the Wellbeing Mentors at weekly supervi-
sion meetings. A small number of sessions may be
audio- or video-recorded as an additional assessment of
intervention fidelity. Feedback from intervention obser-
vations will be used in subsequent supervision sessions
to improve adherence to the intervention protocols.
Intervention compliance by trial participants will be
measured by assessing adherence to the PM+ protocol
with regards to attendance at sessions.
Control arm
Participants randomised to the control arm will not be
offered any PM+ but will be able to access all usual care
and support offered by the participating NGOs. To con-
trol for the weekly contact that the active arms will re-
ceive, participants randomised to the control arm will be
invited by the interviewing researcher to attend a local
AS&R NGO of their choice. They will be put in contact
with other AS&Rs from similar backgrounds and en-
couraged to meet together on a weekly basis for 5
weeks.
Participant identification
Potential participants will be identified primarily through
NGOs and primary care teams, all designated as
Table 3 PROSPER progression criteria
Progression criteria Go Amend Stop
Recruitment of trial
participants
≥ 70% of target 50–69% of target < 50% of target
Retention of trial participants ≥ 70% retained 50–69% retained < 50% retained
Protocol adherence ≥ 70% of intervention delivered per
protocol
50–69% of intervention delivered per
protocol
< 50% of intervention delivered per
protocol
Completion of outcome
measures
≥ 70% of measures are complete 50–69% of measures are complete < 50% of outcome measures are
complete
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Participant Information Agencies (PIAs). PIAs will be
provided with a short summary of the study including
the main inclusion and exclusion criteria. They will be
asked to display posters and leaflets and discuss the
study opportunistically with AS&Rs who access the ser-
vices. All participant-facing documentation will have the
necessary approvals from a Research Ethics Committee
(REC).
Potential participants will be made known to the re-
search team via one of the following methods:
 By them contacting the research team directly via
telephone or email
 By agreeing to their details being given to the
research team (via a participant recommendation
form, completed by the PIA with the AS&R, and
returned to the research team by the PIA)
 By attending a researcher-attended drop-in session
at collaborating NGOs on a specific date/time, ad-
vertised by posters/leaflets/verbally
Following identification of a potential participant, a
postdoctoral researcher based in the University of Liver-
pool, who is trained in the PROSPER trial techniques
and in discussion about informed consent, will arrange a
meeting to give more information about the trial.
Informed consent
The researcher will contact the potential participant to
arrange an individual face-to-face meeting. This meeting
will be arranged at the convenience of the AS&R where
possible and can be attended by an interpreter if re-
quired. The meeting will last between 1 and 2 h. It will
take place at a convenient location which could include
one of the NGO centres, a community centre, a counsel-
ling centre, NHS premises and the University of
Liverpool.
Objectives, risks and inconveniences of the trial and
the conditions under which it is to be conducted will be
provided by the researcher. All potential participants will
be given the opportunity to ask any questions that may
arise, will have the opportunity to discuss the study with
others and be given time to consider the information
prior to agreeing to participate. It will be made clear to
the participant that an eligibility assessment will be con-
ducted once consent is given and that if the participant
is found to be ineligible for any reason that they will be
unable to participate.
The potential participant will be asked to read and re-
view the Participant Information Sheet (PISC), which is
available in English and the study languages of Farsi,
Urdu and Arabic. Upon reviewing the document, the re-
searcher will explain the research study to the potential
participant. The PISC and the discussion with the
participant will emphasise that participation in the trial
is voluntary and that the participant may withdraw from
the trial at any time and for any reason. Participants will
also be asked for permission for the research team to
share relevant data with people from the Universities
taking part in the research or from regulatory author-
ities, where relevant. This trial does not involve collect-
ing biological specimens for storage. The researcher is
aware of the sensitive nature of the research topic and
will minimise any distress caused to potential partici-
pants as a result of the discussions.
If the asylum seeker or refugee decides that they would
like to participate, they will then personally sign and
date the informed consent document. The document
will then be signed and dated by the person obtaining
consent. A copy of the informed consent document will
be given to the potential participant for their records.
The original document will be maintained by the re-
search team separate from any personal identifiable in-
formation collected for any participants. A further copy
will be sent to the Liverpool Clinical Trial Centre
(LCTC) via secure methods if the participant is eligible
for full trial participation; this will be sent separately
from any participant data subsequently collected. The
PISC (which includes informed consent documentation)
is available from the corresponding author on request.
If the potential participant requires more time to con-
sider involvement in the trial a further meeting can be
arranged at the discretion of the researcher. If the indi-
vidual does not wish to take part, their reason for not
providing consent will be recorded on the PROSPER
Screening Log. Once consent has been given the partici-
pant may, without being subject to any resulting detri-
ment, withdraw from the trial at any time by revoking
the informed consent.
Eligibility and baseline assessments
Once written informed consent has been obtained, the
potential participant can be assessed for eligibility, as per
the criteria detailed above.
Eligibility assessment will follow a staged process. The
researcher will review responses at the end of each stage
and, if the potential participant is found to be ineligible,
they will be informed of this and there will be no re-
quirement for completion of the next stage.
Firstly, through discussion with the potential partici-
pant, the researcher will answer socio-demographic
questions. The researcher will then assess the following
exclusion criteria: complex mental disorder (bipolar dis-
order/manic depression, or schizophrenia); cognitive im-
pairment (moderate/severe intellectual disability, any
dementia); substance misuse; currently receiving a for-
mal psychological therapy. If the potential participant re-
mains eligible, they will be asked to self-complete the
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HADS, WHODAS and PHQ-9 questionnaires within the
Eligibility Questionnaire Booklet. These questionnaires
are all available in English, Arabic, Farsi and Urdu. The
researcher will review the completed PHQ-9 question-
naire to assess whether the potential participant is at
imminent risk of suicide. If there are any concerns re-
garding suicide risk, the researcher will follow the pro-
cedure outlined in the Suicidal Ideation Guidance
Document.
If the potential participant is eligible following this
process, the researcher will conduct the baseline as-
sessments outlined in the following section. This
will allow consistency for outcome measurement
completion, and also reduce the need for attendance
at additional meetings. If the researcher has any
concerns or uncertainties from the non-clinical eli-
gibility assessment above, they will contact the chief
investigator (CI) or nominated deputy to discuss the
case.
AS&Rs who are assessed as ineligible can be reconsid-
ered for participation at a later date if circumstances
change, e.g. if they are able to register with a GP. If this
is more than 2 weeks after consent was obtained, the
consent process will be repeated.
Following the completion of the eligibility assessment,
the researcher will ask the eligible participant to self-
complete the Baseline Questionnaire Booklet, which in-
corporates the remaining baseline assessments: the
WHO-5, PSYCHLOPS and PCL-5 questionnaires. The
CSRI Form, which has been adapted for PROSPER, will
be completed by the researcher through discussion with
the participant.
For a potential participant who completes the eligibil-
ity assessment process and is deemed eligible to partici-
pate in PROSPER Pilot, but where there was concern or
uncertainty that necessitated the researcher contacting
the CI or nominated deputy, the CI or nominated dep-
uty will review the information provided by the partici-
pant to verify eligibility for trial participation and
complete the Eligibility and Baseline CRF before ran-
domisation occurs.
Randomisation
Participants will be randomised using a secure, web-
based randomisation programme. Randomisation lists
will be generated in a 1:1:1 ratio, to individual PM+,
group PM+ and control, using block randomisation with
random variable block sizes.
The randomisation list will be generated by a statisti-
cian independent to the PROSPER trial. Given the open
nature of the trial, it will not be possible to blind re-
searchers, trial participants, care providers, outcome as-
sessors or data analysts to the intervention arm to which
participants are assigned.
The researcher will update the PROSPER Screening
Log when a participant has been randomised. The re-
searcher will be responsible for notifying the participant
of their allocation. In the event that a participant is ran-
domised to individual or group PM+, the researcher will
inform the PSS Lead. Intervention delivery will be coor-
dinated by PSS in collaboration with the participant and
their lay therapist. The research team will notify the par-
ticipant’s GP by letter of their enrolment into the trial
and to what treatment arm they have been allocated.
Assessments and follow-up
All assessments and follow-up will be conducted in line
with the schedule of assessments summarised in
Table 4.
In the case of premature discontinuation/withdrawal,
there are no additional assessments for participants.
All specified outcomes will be measured at 13 (± 2)
and 26 (± 2) weeks post baseline; 13 weeks will be the
primary end point: this is consistent with previous trials
[28]. It allows time for intervention delivery and often
may correspond to the timings of Home Office decisions
on leave to remain for asylum seekers.
Follow-up visit: 1–13-week follow-up
This is expected to be a face-to-face appointment at 13
weeks ± 2 weeks from baseline, and include:
 Verbal confirmation of continued consent
 The participant will complete the following
questionnaires within the Follow-up Questionnaire
Booklet: HADS, WHODAS, PHQ-9, WHO-5, PSY-
CHLOPS, PCL-5
 If suicidal ideation is disclosed or suspected, the
researcher will follow the steps outlined in the
Suicidal Ideation Guidance document
 Recording of any adverse event information
 Researcher-led completion of the adapted CSRI
 Completion of Follow-up CRF
Follow-up visit: 2–26-week follow-up
This is expected to be a face-to-face appointment at 26
weeks ± 2 weeks from baseline, and to follow the same
process as the follow-up appointment at 13 weeks.
All follow-up appointments will be coordinated and
conducted by the trained researcher. They will conduct
a preliminary review of the data collected to screen for
missing data or any responses that may need further
follow-up or clinical discussion. Follow-up appointments
are expected to take around 1 h which should allow for
completion of all data collection and review of any ad-
verse events. If a face-to-face appointment cannot be ar-
ranged during the follow-up window then the visit can
be conducted by telephone if possible. If the research
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team is unable to make arrangements to administer the
assessments, the option of the participant self-
completing the assessments and returning them by post
will be explored. It is expected that participant responses
will be completed during the appropriate visit window.
The PROSPER Pilot study design is summarised in
Fig. 1.
Statistical considerations
A detailed statistical analysis plan (SAP) will be devel-
oped prior to the first comparative monitoring report to
be presented to the Independent Data and Safety Moni-
toring Committee (IDSMC). The main features of these
planned statistical analyses, which refer specifically to
the PROSPER Pilot, are detailed below.
The aim is to recruit 105 participants, 35 to each of
three arms – individual PM+, group PM+ and control.
Individual sessions will be offered as gender- and
language-specific, i.e. the lay therapist and the study par-
ticipant will be the same gender and will be comfortable
in a common language. At least four groups will be of-
fered for the group intervention, each with up to eight
or nine participants, each gender-specific, i.e. partici-
pants will all be the same gender and at least one of the
lay therapists will be of the same gender as the
participants.
The sample size needs to be sufficient to estimate re-
tention levels in a definitive trial. With an expectation of
80% retention, samples of 35 participants for each of the
individual, group and control arm will provide an accur-
ate estimate of retention ± 13% (67 to 93%).
Retention rates will be assessed in each arm separately,
as there may be systematic differences between them;
for example, those randomised to the control arm may
be less likely to remain engaged than those randomised
to the individual or group arms, while those randomised
to the group arm may be demotivated if faced with a
lengthy wait for their group to begin.
No formal interim analysis is planned as this is a pilot
study and there are no anticipated problems that are
detrimental to the participant. There will be monitoring
by the IDMSC, who will provide a recommendation to
the Trial Steering Committee (TSC) on the continuation
of the trial.
Analysis will be by the intention-to-treat principle
as far as is practically possible. All analyses will be
descriptive, focussed on assessing the criteria for de-
ciding whether to progress to a full trial. All estimates
of proportions will be presented with 95% confidence
intervals. Rates of recruitment and attrition will be
presented both for lay therapists and trial participants,
along with the proportion of PM+ interventions
which are successfully delivered per protocol. The
Table 4 Schedule of assessments
Screening and baseline Randomisation 13-week follow-up 26-week follow-up
Time point (weeks) 0 0 13 ± 2 26 ± 2
Procedures:
Consent, eligibility screening and confirmation
Written and Informed consent X
Assess eligibility X
Confirm eligibility X
Randomisation X
Confirm consent X X X
Data collection
HADS X X X
WHODAS X X X
PHQ-9 X X X
PSYCHLOPS X X X
PCL-5 X X X
WHO-5 X X X
CSRI X X X
Adverse events
Assessment of AEs X X X
Abbreviations: AEs adverse events, CSRI Client Service Receipt Inventory, HADS Hospital Anxiety and Depression Scale, PCL-5 Post-traumatic Stress Disorder
Checklist for DSM-5, PHQ-9 9-item Patient Health Questionnaire, PSYCHLOPS Psychological Profiles Instrument,, WHO-5 World Health Organisation Five Wellbeing
Index, WHODAS World Health Organisation Disability Assessment Schedule
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proportion of missing data in the proposed trial out-
come measures will be assessed.
Preliminary exploration of estimates of efficacy will
involve a group-wise comparison of the primary out-
come: severity of combined anxiety and depressive
symptoms at 13 weeks post baseline measured using
the HADS.
Socio-demographic data, and use of services and sup-
ports will be captured by the adapted Client Service Re-
ceipt Inventory [37]. This data can be used for a wide
range of applications, including estimating the costs of
service receipt and societal costs.
No formal testing of intervention effect will be car-
ried out, but estimates of between-group differences
between the test groups and the control in outcome
measures will be presented, with 95% confidence in-
tervals, to assess whether a clinically important im-
provement in outcome would be plausible in a full
trial. The effect of clustering by intervention provider
on outcomes in the two PM+ groups will be
Fig. 1 Schematic of the study design
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investigated, to inform design of a full trial with a
partially nested design.
Process evaluation and feasibility assessment
Relevance and acceptability of proposed outcomes will
be tested, with a view to their incorporation or refine-
ment for a definitive trial. These will include:
 Effectiveness of PM+, based on the primary
outcome of combined HADS scores
 Cost-effectiveness of PM+ from a NHS perspective,
based on the primary outcome of combined HADS
scores [40, 41]
 Cost benefit from a societal perspective, given
that costs and potential benefits will extend
beyond the NHS to local government and
voluntary sectors [42–44]
 Impact on health inequalities using the NIHR
CLAHRC NWC Health Inequalities Assessment
Toolkit (www.hiat.org.uk): first, within AS&R
communities in relation to age, gender, nationality,
education, prior occupation and asylum status; and
second, between AS&Rs and national populations,
comparing mental health status (anxiety, depression
PTSD and wellbeing) with UK population norms,
with reference to published psychiatric morbidity
data [45]
The feasibility of the 13- and 26-week time points will
be assessed, with specific reference to rates of participant
attrition.
Researchers will undertake a systems-based process
evaluation [46], beginning 3 months into the PROSPER
Pilot, to: understand service provider and participant ex-
periences and perspectives on acceptability, efficiency,
implementation and development of PM+; understand
service-users’ perceptions and experiences of accessing
and participating in PM+; explore how PM+ fits into
existing health/social care systems; and understand
change-process dynamics including barriers and facilita-
tors to implementing PM+. An ethnographic method
will be adopted including observation of PM+ imple-
mentation alongside semi-structured interviews and
focus group discussions with key stakeholder groups
such as lay therapists, Wellbeing Mentors, PM+ partici-
pants, representatives from NGOs working with AS&R
communities, health professionals and commissioners
from Liverpool City Region. Heterogeneity within the
population will be considered and whether the interven-
tion’s feasibility and effectiveness may differ by demog-
raphy or asylum status, and how this may influence the
choice of target population for our proposed definitive
trial.
Analysis will be based on narrative synthesis, combin-
ing data tabulation and narrative techniques. This will
involve iterative review and refinement in order to reach
agreement on a set of general propositions in relation to
the data. The perspectives of Normalisation Process
Theory [47, 48] will be used to assess the potential for
implementing a full RCT, focussing on the progression
criteria set out above.
Discontinuation and withdrawal
In consenting to the trial, participants agree to all trial
activities including administration of trial intervention
and follow-up assessments/visits and data collection.
Every effort will be made to facilitate the completion of
these for every recruited participant. If it is not possible
to complete these activities (or it is deemed inappropri-
ate) the reasons why should be documented.
Participants may discontinue the study intervention
for reasons including, but not limited to:
 Participant-led, i.e. request by the participant
 Researcher/clinician/lay therapist-led:
– Any change in the participant’s condition that
justifies the discontinuation of the intervention in
the researcher/clinician/lay therapist’s opinion
– Reasons of non-adherence or non-compliance
with study intervention or other trial procedures,
e.g. unable to complete course of PM+
– Participant meets an exclusion criterion (either
newly developed or not previously recognised)
Discontinuation from PM+ does not mean discontinu-
ation of the study altogether, and the remaining study
procedures, i.e. 13- and 26-week follow-up visits and
data collection, and process evaluation, will be com-
pleted as indicated in the protocol (unless consent is
specifically withdrawn).
Participants are free to withdraw from follow-up at
any time without providing a reason, though a reason
should be recorded if one is given. Those who wish to
withdraw from further follow-up will have the data col-
lected up to the point of that withdrawal included in the
analyses. The participant will not contribute further data
to the study and the LCTC will be informed, via email
to the LCTC and via completion of a Withdrawal CRF
to be returned to the LCTC within 24 h. Death of a par-
ticipant would be recorded on a Withdrawal CRF and a
Death CRF.
For participants moving from the area, every effort will
be made for the participant to be followed up and to
complete their remaining study appointment(s)
remotely.
A participant will be considered lost to follow-up if
they fail to return for any scheduled visits and are not
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contactable by the site research team. If a participant
fails to attend/facilitate a required study visit the follow-
ing actions must be taken:
 The researcher will attempt to contact the
participant and reschedule the missed visit (be
conscious of acceptable windows for collecting valid
data) and advise the participant on the importance
of maintaining the assigned visit schedule
 Before a participant is deemed to be lost to follow-
up, the research team will make reasonable effort to
regain contact with the participant
 If the participant continues to be unreachable they
should be considered withdrawn from the study
with a primary reason of lost to follow-up and this
should be recorded on the Withdrawal CRF
Confidentiality and access to data
Forms which contain participant identifiers will be
stored separately from the Case Report Forms (CRFs).
The database will be secured with password protection.
Participants’ data will not be released outside of the
study without the written permission of the participant,
documented in the consent form.
The University of Liverpool and Bangor University are
registered as data controllers with the Information Com-
missioner’s Office.
Safety and monitoring
Safety assessments will be based on information dis-
closed by the participant throughout trial duration and
by those who have knowledge of their welfare, including
GPs, other health professional and NGO members. The
CI and other research staff are responsible for monitor-
ing and reporting all adverse events.
Ancillary and post-trial care will be the responsibility
of the participant’s registered GP.
Data will be centrally monitored by the LCTC to pro-
mote data quality. Monitoring processes are documented
in the ‘Trial Monitoring Plan’ and can be made available
from the authors on request. If necessary, on-site moni-
toring visits can be triggered and will be carried out by
either the LCTC or the sponsor representative.
Safety information and data will be independently
monitored by the IDSMC. The IDSMC is chaired by an
independent senior clinical academic, and includes an
independent methodological expert and an experienced
service user. The IDSMC will report to the TSC, and
hence to the NIHR Public Health Research Programme
Board. The composition and terms of reference for both
the IDSMC and the TSC are available from the authors
on request.
End of trial
The end of the trial is defined to be the date on which
data for all participants is locked and data-entry privi-
leges are withdrawn from the trial database. However,
the trial may be closed prematurely by the TSC on the
recommendation of the IDSMC.
Dissemination
Using established procedures for knowledge exchange
we will disseminate the findings of our research through:
 Dedicated project web-page and social media sites
 Feedback to participants, both service users and
providers
 Presentations to stakeholder groups including
service users and providers, policy-makers and com-
missioners, funders and benefactors
 Presentations to national asylum seeker and refugee
NGOs
 Presentations at clinical academic conferences
 Report for NIHR Public Health Research journal
 Submission of research papers to high-impact peer-
reviewed journals
Discussion
The PROSPER feasibility study and Pilot Trial should
generate new knowledge of benefit to the NHS and to
society in general. This study will ascertain whether lay
therapists based in NGOs can be trained to deliver PM+
with demonstrable evidence of capacity. It should pro-
vide early indications as to whether PM+ can lead to im-
provements in mental health and function for distressed
AS&Rs in current UK settings. It should identify poten-
tial new pathways for access to care for these vulnerable
groups, overcoming existing barriers such as accessibility
of delivery locations and language barriers.
There is currently a lack of evidence on feasibility of
conducting research into psychosocial interventions in
these circumstances, and this study will address this gap
in the evidence base. We anticipate that the study will
provide clear evidence on the key parameters needed for
a definitive RCT in this field. Such a definitive trial has
the potential to improve mental health, wellbeing and
functional ability amongst AS&Rs, and to reduce health
inequalities. This is likely to lead to more equitable and
effective use of health care, with a shift from receiving
emergency care to managed, proactive and preventive
care. From a societal perspective, cost-effectiveness and
cost-benefit analyses following the definitive trial will in-
dicate the extent to which the intervention confers both
direct and indirect benefits. Public and patient involve-
ment should ensure that the project delivers high-
quality, original evidence that has the potential to have a
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significant impact on the design of the definitive inter-
vention and, subsequently, on policy and practice.
From an international perspective, our findings should
have relevance for other HICs hosting refugees, as well
as for WHO recommendations on the use of PM+ with
AS&R communities who experience significant
adversities.
Trial status
 Protocol version V5.0, dated: 11 December 2019
 Recruitment start: 27 November 2019
 Recruitment completion (expected): 31 May 2020
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